<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02227394</url>
  </required_header>
  <id_info>
    <org_study_id>Z7200K02</org_study_id>
    <secondary_id>2014-002151-26</secondary_id>
    <nct_id>NCT02227394</nct_id>
  </id_info>
  <brief_title>Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients</brief_title>
  <official_title>A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Z7200 and Symbicort® Turbohaler on Functional Respiratory Imaging Parameters in Asthmatic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FLUIDDA nv</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      The primary objective of this study is to evaluate the effect of the products under&#xD;
      investigation on functional respiratory imaging parameters and evaluate the particle&#xD;
      deposition with Computational fluid dynamics (CFD).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      The secondary objectives of this study were to assess the effect of test product and&#xD;
      reference product on:&#xD;
&#xD;
        -  lung function (spirometry and body plethysmography),&#xD;
&#xD;
        -  exercise capacity (6-Minute Walking Test [6MWT] or equivalent method to measure exercise&#xD;
           tolerance),&#xD;
&#xD;
        -  dyspnea (Borg Category [C] Ratio [R] 10 [Borg CR10] scale and Visual Analogue Scale&#xD;
           [VAS] dyspnea).&#xD;
&#xD;
      Furthermore, the safety of the test product and reference product was evaluated through&#xD;
      monitoring of AEs throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted as a randomized, double blind, double dummy two-period crossover&#xD;
      study in stable asthma patients treated in accordance with the Global Initiative for Asthma&#xD;
      (GINA) guidelines.&#xD;
&#xD;
      On the first dosing day (Period 1, Visit 2), asthma stability was assessed based on review of&#xD;
      pharmacologic treatment monitoring and FEV1 change from the previous visit. Patients were&#xD;
      then randomized and allocated to one of two treatment sequences (i.e. test/reference or&#xD;
      reference/test). Randomization codes were assigned strictly sequentially as patients became&#xD;
      eligible for randomization. Patients received a single dose consisting of two inhalations of&#xD;
      either the test product or the reference product, according to the assigned treatment&#xD;
      sequence, in the presence of the Investigator or authorized site personnel. In addition,&#xD;
      patients received two inhalations with matching placebo to the alternate treatment as a dummy&#xD;
      inhaler to achieve double-blinding. All patients followed the same sequence of device&#xD;
      inhalation, i.e. Symbicort or placebo Turbohaler first and Z7200 or placebo RS-01 inhaler&#xD;
      second.&#xD;
&#xD;
      On the second dosing day (Period 2, Visit 3), patients underwent the same asthma stability&#xD;
      check and procedures as in Visit 2. Patients received a single dose consisting of two&#xD;
      inhalations of the other treatment (reference in case test product was administered at Visit&#xD;
      2 and vice versa) plus two inhalations with matching placebo to the alternate treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Airway Volume (iVaw)</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>The Total Airway Volume is the amount of air that can be inhaled or exhaled during one respiratory cycle. This depicts the functions of the respiratory centers, respiratory muscles and the mechanics of the lung and chest wall. The higher the volume, the better the outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Airway Resistance (iRaw)</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>The Total Airway Resistance refers to degree of resistance to the flow of air through the respiratory tract during inspiration and expiration. The degree of resistance depends on many things, particularly the diameter of the airway and whether flow is laminar or turbulent. The higher the resistance, the worse the outcome.&#xD;
In healthy men and women values range between 0.22 to 0.25 kPa/l.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Deposited Particles Per Pre-defined Airway Section</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>To evaluate the particle deposition in the lungs, the Computational Fluid Dynamic (CFD) was used. With CFD, based on the computed tomography (CT) derived geometries of the airways, it is possible to measure the resistance of all airways or subdivisions such as the smaller airways starting from the 3rd bifurcation onwards. The three-dimensional (3D) reconstruction in this CT-based imaging technique allows for an accurate measurement of local volume changes in the central and peripheral airways after the administration of the product. The increased sensitivity of this technique makes it possible to detect changes in airway caliber in early stages of asthma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry - FEV1</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>FEV1 = Forced Expiratory Volume in one second. Forced expiratory volume is the most important measurement of lung function. It measures how much air a person can exhale during a forced breath. The amount of air exhaled may be measured during the first (FEV1), second (FEV2), and/or third seconds (FEV3) of the forced breath.&#xD;
Values of between 80% and 120% of the average value are considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry - FVC</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>FVC = Forced Vital Capacity: is the total amount of air exhaled during the FEV test.&#xD;
Values of between 80% and 120% of the average value are considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry - PEF</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>PEF = Peak Expiratory Flow: is the maximum flow rate generated during a forceful exhalation, starting from full lung inflation.&#xD;
PEF rate primarily reflects large airway flow and depends on the voluntary effort and muscular strength of the patient.&#xD;
Normal adult peak expiratory flow ranges between around 400 and 700 liters per minute, although in older it can be lower.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry - MEF25</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>MEF25 = Maximal Expiratory Flow at 25% of Forced Vital Capacity (FVC). This parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry - MEF50</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>MEF50 = Maximal Expiratory Flow at 50% of Forced Vital Capacity (FVC). MEF50 is the flow where half of forced vital capacity (FVC) remains to be exhaled. Also this parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry - FEV1/FVC Ratio</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>FEV1/FVC ratio = Tiffeneau Index. It is a calculated ratio use to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity. The result of this ratio is expressed as FEV1%.&#xD;
Normal values are approximately 75%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Plethysmography - FRC</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>FRC = Functional Residual Capacity. It is the volume in the lungs at the end of passive expiration. It is determined by opposing forces of the expanding chest wall and the elastic recoil of the lung. A normal FRC = 1.7 to 3.5 L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Plethysmography - TLC</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>TLC = Total Lung Capacity. It is the volume of air in the lungs upon the maximum effort of inspiration. Among healthy adults, the average lung capacity is about 6 liters. Age, gender, body composition, and ethnicity are factors affecting the different ranges of lung capacity among individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Plethysmography - Raw</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>Raw = Airway resistance. It is defined as the change in transpulmonary pressure (proximal airway pressure minus the alveolar pressure) required to produce a unit flow of gas through the airways of the lung.&#xD;
Are considered as normal all values up to 2.8 kPas/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Plethysmography - SRaw</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>SRaw = Specific airway resistance: also called volumic airway resistance. sRaw is a corrected index (Raw multiplied by thoracic gas volume) that describes airway behaviour regardless of lung volume. Normal values of sRaw in adult subjects have never been formally defined.&#xD;
sRaw is the product of Functional Residual Capacity (FRC) and Airways Resistance (Raw) and can be calculated from the relationship of plethysmographic box pressure (Pbox) to flow during spontaneous breathing.&#xD;
sRaw can be derived from the tangent of the slope of box Pressure/Flow. Since Raw has a strong inverse relationship to lung volume, sRaw provides a relatively stable index with which to distinguish effects of disease from those of growth and development. sRaw is significantly increased in asthmatic patients, in those with wheezing disorders, and cystic fibrosis. It has also been shown to be a useful outcome measure for bronchodilator responsiveness studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhalation Profile</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>The patients' inhalation profile was assessed using a respiration belt. The inhalation profile through device was to be recorded at the moment of study drug administration. Respiratory belts are useful in measuring changes in thoracic or abdominal circumference during respiration. These measurements can indicate inhalation, expiration and breathing strength and can be used to derive breathing rate and characterize breathing patterns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWT</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>6MWT = 6 Minutes Walk Test (in meters). The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. The longer the walk in that timespan, the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg CR10 Scale (Pre-6MWT)</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case before the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, &quot;0 or nothing at all,&quot; means no breathlessness at all.&#xD;
The bottom of the scale, &quot;10 or maximal,&quot; means the most severe breathlessness that patients have ever experienced or could imagine experiencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg CR10 Scale (Post-6MWT)</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case after the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, &quot;0 or nothing at all,&quot; means no breathlessness at all.&#xD;
The bottom of the scale, &quot;10 or maximal,&quot; means the most severe breathlessness that patients have ever experienced or could imagine experiencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Pre-6MWT)</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (In this case before the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from &quot;not breathless at all&quot;/no shortness of breath&quot; at the bottom or at the far left of the line, to &quot;shortness of breath as bad as can be&quot; on the top or on the right of the line, depending on the patient's opinion.&#xD;
measure of the difference in dyspnoea before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Post-6MWT)</measure>
    <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
    <description>VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (in this case after the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from &quot;not breathless at all&quot;/no shortness of breath&quot; at the bottom or at the far left of the line, to &quot;shortness of breath as bad as can be&quot; on the top or on the right of the line, depending on the patient's opinion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Asthma</condition>
  <condition>Asthma Chronic</condition>
  <condition>Asthma Bronchial</condition>
  <condition>Asthmatic</condition>
  <arm_group>
    <arm_group_label>Z7200 - Symbicort® Turbohaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the test product (Z7200) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the second dosing day (Period 2, Visit 3).&#xD;
Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.&#xD;
Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort® Turbohaler - Z7200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the test product (Z7200) on the second dosing day (Period 2, Visit 3).&#xD;
Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.&#xD;
Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z7200</intervention_name>
    <description>Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).&#xD;
At visit 2 or 3 (cross-over design)</description>
    <arm_group_label>Symbicort® Turbohaler - Z7200</arm_group_label>
    <arm_group_label>Z7200 - Symbicort® Turbohaler</arm_group_label>
    <other_name>Test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort® Turbohaler®</intervention_name>
    <description>Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)</description>
    <arm_group_label>Symbicort® Turbohaler - Z7200</arm_group_label>
    <arm_group_label>Z7200 - Symbicort® Turbohaler</arm_group_label>
    <other_name>Reference product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient ≥ 18 years old.&#xD;
&#xD;
          2. Written informed consent obtained.&#xD;
&#xD;
          3. Patient with a documented diagnosis of asthma according to the Global Initiative for&#xD;
             Asthma (GINA) guidelines&#xD;
&#xD;
          4. Patient with a co-operative attitude and ability to correctly use the DPI.&#xD;
&#xD;
          5. Female patient of childbearing potential who confirm that a reliable method of&#xD;
             contraception was used at least 14 days before visit 1 and will continue to use a&#xD;
             reliable method of contraception during the study, or post-menopausal women (at least&#xD;
             12 months of amenorrhea)&#xD;
&#xD;
          6. Patient must be stable and treated in accordance with the GINA guidelines.&#xD;
&#xD;
          7. Patient must be a non-smoker or ex-smoker who have stopped smoking at least 1 month&#xD;
             prior to visit 1 and has a smoking history of &lt; 10 pack years.&#xD;
&#xD;
          8. Patient must be able to understand and complete the protocol requirements,&#xD;
             instructions, questionnaires and protocol-stated restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating female.&#xD;
&#xD;
          2. Unstable patient who developed an asthma exacerbation in the 4 weeks before screening.&#xD;
&#xD;
          3. Patient with upper or lower airways infection in the 4 weeks before screening.&#xD;
&#xD;
          4. Patient unable to perform pulmonary function testing.&#xD;
&#xD;
          5. Patients unable to withdraw fixed combination or long acting bronchodilator inhalation&#xD;
             products&#xD;
&#xD;
          6. Patient with an uncontrolled disease or any condition that might, in the judgement of&#xD;
             the investigator, place the patient at undue risk or potentially compromise the&#xD;
             results or interpretation of the study.&#xD;
&#xD;
          7. Patient with active lung cancer or any other chronic disease with poor prognosis and&#xD;
             /or affecting patient status.&#xD;
&#xD;
          8. Patient with allergy, sensitivity or intolerance to study drugs and/ or study drug&#xD;
             formulation ingredients.&#xD;
&#xD;
          9. Patient unlikely to comply with the protocol or unable to understand the nature, scope&#xD;
             and possible consequences of the study.&#xD;
&#xD;
         10. Patient who received systemic corticosteroids within the last 4 weeks prior to visit&#xD;
&#xD;
         11. Patient who received any investigational new drug within the last 4 weeks prior to&#xD;
             visit 1 and is participating in any clinical trial.&#xD;
&#xD;
         12. Patient with a history of alcohol or substance abuse that in the opinion of the&#xD;
             investigator may be of clinical significance&#xD;
&#xD;
         13. Patient with diagnosis of Chronic Obstructive Pulmonary Disease (COPD).&#xD;
&#xD;
         14. Patients who has a lactose intolerance or history of allergy to milk proteins.&#xD;
&#xD;
         15. Patients treated with medications or herbal medicines that are strong cytochrome P450&#xD;
             3A4 (CYP3A4) inhibitors (e.g., ritonavir, indinavir, nelfinavir, saquinavir,&#xD;
             atazanavir, ketoconazole, itraconazole, voriconazole, fluconazole, cyclosporine,&#xD;
             mibefradil, nefazodone, clarithromycin, telithromycin, troleandromycin, norfloxacin,&#xD;
             ciprofloxacin) or inducers (e.g. phenobarbital, phenytoin, barbiturates,&#xD;
             carbamazepine, oxcarbazepine, rifabutin, rifampin, St John's wort) within 2 weeks&#xD;
             prior to Screening Visit and during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried De Backer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <results_first_submitted>October 6, 2021</results_first_submitted>
  <results_first_submitted_qc>November 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2022</results_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Functional Respiratory Imaging</keyword>
  <keyword>Computational Fluid Dynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study procedures were explained to the patients on the screening visit day (Visit 1). Patients who wanted to participate in the study were asked to sign the ICF. Patients were given the chance to ask questions and to clarify their doubts regarding the study either at the screening visit or at any time during the study. Study procedures commenced only after the patient had signed the ICF.</recruitment_details>
      <pre_assignment_details>Only patients who met all inclusion criteria and none of the exclusion criteria were enrolled in the study and entered the run-in period of 7 (minimum) to 31 (maximum) days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Z7200 - Symbicort® Turbohaler</title>
          <description>the patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the test product (Z7200) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the second dosing day (Period 2, Visit 3).&#xD;
Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.&#xD;
Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.&#xD;
Z7200: Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).&#xD;
At visit 2 or 3 (cross-over design)&#xD;
Symbicort® Turbohaler®: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)</description>
        </group>
        <group group_id="P2">
          <title>Symbicort® Turbohaler - Z7200</title>
          <description>the patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the first dosing day (Period 1, Visit 2), then, after a washout period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the test product (Z7200) on the second dosing day (Period 2, Visit 3).&#xD;
Patients were also to receive 2 inhalations with a matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.&#xD;
Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg).&#xD;
Z7200: Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).&#xD;
At visit 2 or 3 (cross-over design)&#xD;
Symbicort® Turbohaler®: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population consisted of all 20 randomized patients who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>The results of demographic and baseline characteristics are presented for the safety population overall.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Airway Volume (iVaw)</title>
        <description>The Total Airway Volume is the amount of air that can be inhaled or exhaled during one respiratory cycle. This depicts the functions of the respiratory centers, respiratory muscles and the mechanics of the lung and chest wall. The higher the volume, the better the outcome.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Total Airway Volume (iVaw)</title>
          <description>The Total Airway Volume is the amount of air that can be inhaled or exhaled during one respiratory cycle. This depicts the functions of the respiratory centers, respiratory muscles and the mechanics of the lung and chest wall. The higher the volume, the better the outcome.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.033" spread="13.231"/>
                    <measurement group_id="O2" value="48.577" spread="13.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.101" spread="12.738"/>
                    <measurement group_id="O2" value="50.831" spread="13.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.068" spread="1.659"/>
                    <measurement group_id="O2" value="2.255" spread="2.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.727</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.187</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.098</ci_lower_limit>
            <ci_upper_limit>0.724</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Airway Resistance (iRaw)</title>
        <description>The Total Airway Resistance refers to degree of resistance to the flow of air through the respiratory tract during inspiration and expiration. The degree of resistance depends on many things, particularly the diameter of the airway and whether flow is laminar or turbulent. The higher the resistance, the worse the outcome.&#xD;
In healthy men and women values range between 0.22 to 0.25 kPa/l.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Total Airway Resistance (iRaw)</title>
          <description>The Total Airway Resistance refers to degree of resistance to the flow of air through the respiratory tract during inspiration and expiration. The degree of resistance depends on many things, particularly the diameter of the airway and whether flow is laminar or turbulent. The higher the resistance, the worse the outcome.&#xD;
In healthy men and women values range between 0.22 to 0.25 kPa/l.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>kPas/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.016"/>
                    <measurement group_id="O2" value="0.037" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.011"/>
                    <measurement group_id="O2" value="0.026" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.007"/>
                    <measurement group_id="O2" value="-0.011" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.366</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.003</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.007</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Deposited Particles Per Pre-defined Airway Section</title>
        <description>To evaluate the particle deposition in the lungs, the Computational Fluid Dynamic (CFD) was used. With CFD, based on the computed tomography (CT) derived geometries of the airways, it is possible to measure the resistance of all airways or subdivisions such as the smaller airways starting from the 3rd bifurcation onwards. The three-dimensional (3D) reconstruction in this CT-based imaging technique allows for an accurate measurement of local volume changes in the central and peripheral airways after the administration of the product. The increased sensitivity of this technique makes it possible to detect changes in airway caliber in early stages of asthma.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deposited Particles Per Pre-defined Airway Section</title>
          <description>To evaluate the particle deposition in the lungs, the Computational Fluid Dynamic (CFD) was used. With CFD, based on the computed tomography (CT) derived geometries of the airways, it is possible to measure the resistance of all airways or subdivisions such as the smaller airways starting from the 3rd bifurcation onwards. The three-dimensional (3D) reconstruction in this CT-based imaging technique allows for an accurate measurement of local volume changes in the central and peripheral airways after the administration of the product. The increased sensitivity of this technique makes it possible to detect changes in airway caliber in early stages of asthma.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>Count of Particles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Budesonide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="776339324" spread="111075944"/>
                    <measurement group_id="O2" value="17306552" spread="6985870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Formoterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80448811" spread="14821542"/>
                    <measurement group_id="O2" value="425671" spread="179309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry - FEV1</title>
        <description>FEV1 = Forced Expiratory Volume in one second. Forced expiratory volume is the most important measurement of lung function. It measures how much air a person can exhale during a forced breath. The amount of air exhaled may be measured during the first (FEV1), second (FEV2), and/or third seconds (FEV3) of the forced breath.&#xD;
Values of between 80% and 120% of the average value are considered normal.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry - FEV1</title>
          <description>FEV1 = Forced Expiratory Volume in one second. Forced expiratory volume is the most important measurement of lung function. It measures how much air a person can exhale during a forced breath. The amount of air exhaled may be measured during the first (FEV1), second (FEV2), and/or third seconds (FEV3) of the forced breath.&#xD;
Values of between 80% and 120% of the average value are considered normal.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.935" spread="0.904"/>
                    <measurement group_id="O2" value="2.905" spread="0.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.112" spread="0.896"/>
                    <measurement group_id="O2" value="3.058" spread="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.178" spread="0.115"/>
                    <measurement group_id="O2" value="0.153" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.486</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.025</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry - FVC</title>
        <description>FVC = Forced Vital Capacity: is the total amount of air exhaled during the FEV test.&#xD;
Values of between 80% and 120% of the average value are considered normal.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry - FVC</title>
          <description>FVC = Forced Vital Capacity: is the total amount of air exhaled during the FEV test.&#xD;
Values of between 80% and 120% of the average value are considered normal.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.317" spread="1.113"/>
                    <measurement group_id="O2" value="4.311" spread="1.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.384" spread="1.080"/>
                    <measurement group_id="O2" value="4.328" spread="1.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066" spread="0.173"/>
                    <measurement group_id="O2" value="0.018" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.413</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.049</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.052</ci_lower_limit>
            <ci_upper_limit>0.150</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry - PEF</title>
        <description>PEF = Peak Expiratory Flow: is the maximum flow rate generated during a forceful exhalation, starting from full lung inflation.&#xD;
PEF rate primarily reflects large airway flow and depends on the voluntary effort and muscular strength of the patient.&#xD;
Normal adult peak expiratory flow ranges between around 400 and 700 liters per minute, although in older it can be lower.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry - PEF</title>
          <description>PEF = Peak Expiratory Flow: is the maximum flow rate generated during a forceful exhalation, starting from full lung inflation.&#xD;
PEF rate primarily reflects large airway flow and depends on the voluntary effort and muscular strength of the patient.&#xD;
Normal adult peak expiratory flow ranges between around 400 and 700 liters per minute, although in older it can be lower.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.593" spread="1.978"/>
                    <measurement group_id="O2" value="7.465" spread="1.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.912" spread="1.948"/>
                    <measurement group_id="O2" value="7.883" spread="1.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.319" spread="0.443"/>
                    <measurement group_id="O2" value="0.419" spread="0.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.375</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.100</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.289</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry - MEF25</title>
        <description>MEF25 = Maximal Expiratory Flow at 25% of Forced Vital Capacity (FVC). This parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF25.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry - MEF25</title>
          <description>MEF25 = Maximal Expiratory Flow at 25% of Forced Vital Capacity (FVC). This parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF25.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.700" spread="0.369"/>
                    <measurement group_id="O2" value="0.653" spread="0.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.873" spread="0.490"/>
                    <measurement group_id="O2" value="0.818" spread="0.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from pre-dose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.173" spread="0.190"/>
                    <measurement group_id="O2" value="0.164" spread="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.879</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.009</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.092</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry - MEF50</title>
        <description>MEF50 = Maximal Expiratory Flow at 50% of Forced Vital Capacity (FVC). MEF50 is the flow where half of forced vital capacity (FVC) remains to be exhaled. Also this parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF50.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry - MEF50</title>
          <description>MEF50 = Maximal Expiratory Flow at 50% of Forced Vital Capacity (FVC). MEF50 is the flow where half of forced vital capacity (FVC) remains to be exhaled. Also this parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF50.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.439" spread="1.151"/>
                    <measurement group_id="O2" value="2.350" spread="1.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.878" spread="1.265"/>
                    <measurement group_id="O2" value="2.767" spread="1.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose and postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.440" spread="0.353"/>
                    <measurement group_id="O2" value="0.416" spread="0.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.819</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.023</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.149</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry - FEV1/FVC Ratio</title>
        <description>FEV1/FVC ratio = Tiffeneau Index. It is a calculated ratio use to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity. The result of this ratio is expressed as FEV1%.&#xD;
Normal values are approximately 75%.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry - FEV1/FVC Ratio</title>
          <description>FEV1/FVC ratio = Tiffeneau Index. It is a calculated ratio use to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity. The result of this ratio is expressed as FEV1%.&#xD;
Normal values are approximately 75%.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>FEV1%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.200" spread="10.476"/>
                    <measurement group_id="O2" value="66.800" spread="9.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.600" spread="10.298"/>
                    <measurement group_id="O2" value="70.600" spread="9.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.400" spread="2.927"/>
                    <measurement group_id="O2" value="3.800" spread="2.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.643</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.400</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.870</ci_lower_limit>
            <ci_upper_limit>1.070</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Plethysmography - FRC</title>
        <description>FRC = Functional Residual Capacity. It is the volume in the lungs at the end of passive expiration. It is determined by opposing forces of the expanding chest wall and the elastic recoil of the lung. A normal FRC = 1.7 to 3.5 L.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Body Plethysmography - FRC</title>
          <description>FRC = Functional Residual Capacity. It is the volume in the lungs at the end of passive expiration. It is determined by opposing forces of the expanding chest wall and the elastic recoil of the lung. A normal FRC = 1.7 to 3.5 L.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.661" spread="0.765"/>
                    <measurement group_id="O2" value="3.685" spread="0.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.485" spread="0.707"/>
                    <measurement group_id="O2" value="3.498" spread="0.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.176" spread="0.228"/>
                    <measurement group_id="O2" value="-0.187" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.866</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.011</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.100</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Plethysmography - TLC</title>
        <description>TLC = Total Lung Capacity. It is the volume of air in the lungs upon the maximum effort of inspiration. Among healthy adults, the average lung capacity is about 6 liters. Age, gender, body composition, and ethnicity are factors affecting the different ranges of lung capacity among individuals.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Body Plethysmography - TLC</title>
          <description>TLC = Total Lung Capacity. It is the volume of air in the lungs upon the maximum effort of inspiration. Among healthy adults, the average lung capacity is about 6 liters. Age, gender, body composition, and ethnicity are factors affecting the different ranges of lung capacity among individuals.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.003" spread="1.354"/>
                    <measurement group_id="O2" value="7.008" spread="1.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.007" spread="1.376"/>
                    <measurement group_id="O2" value="6.957" spread="1.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.151"/>
                    <measurement group_id="O2" value="-0.051" spread="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.346</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.054</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.043</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Plethysmography - Raw</title>
        <description>Raw = Airway resistance. It is defined as the change in transpulmonary pressure (proximal airway pressure minus the alveolar pressure) required to produce a unit flow of gas through the airways of the lung.&#xD;
Are considered as normal all values up to 2.8 kPas/L</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Body Plethysmography - Raw</title>
          <description>Raw = Airway resistance. It is defined as the change in transpulmonary pressure (proximal airway pressure minus the alveolar pressure) required to produce a unit flow of gas through the airways of the lung.&#xD;
Are considered as normal all values up to 2.8 kPas/L</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>kPas/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.398" spread="0.419"/>
                    <measurement group_id="O2" value="0.411" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.292" spread="0.266"/>
                    <measurement group_id="O2" value="0.276" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" spread="0.162"/>
                    <measurement group_id="O2" value="-0.135" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.093</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.029</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Plethysmography - SRaw</title>
        <description>SRaw = Specific airway resistance: also called volumic airway resistance. sRaw is a corrected index (Raw multiplied by thoracic gas volume) that describes airway behaviour regardless of lung volume. Normal values of sRaw in adult subjects have never been formally defined.&#xD;
sRaw is the product of Functional Residual Capacity (FRC) and Airways Resistance (Raw) and can be calculated from the relationship of plethysmographic box pressure (Pbox) to flow during spontaneous breathing.&#xD;
sRaw can be derived from the tangent of the slope of box Pressure/Flow. Since Raw has a strong inverse relationship to lung volume, sRaw provides a relatively stable index with which to distinguish effects of disease from those of growth and development. sRaw is significantly increased in asthmatic patients, in those with wheezing disorders, and cystic fibrosis. It has also been shown to be a useful outcome measure for bronchodilator responsiveness studies.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Body Plethysmography - SRaw</title>
          <description>SRaw = Specific airway resistance: also called volumic airway resistance. sRaw is a corrected index (Raw multiplied by thoracic gas volume) that describes airway behaviour regardless of lung volume. Normal values of sRaw in adult subjects have never been formally defined.&#xD;
sRaw is the product of Functional Residual Capacity (FRC) and Airways Resistance (Raw) and can be calculated from the relationship of plethysmographic box pressure (Pbox) to flow during spontaneous breathing.&#xD;
sRaw can be derived from the tangent of the slope of box Pressure/Flow. Since Raw has a strong inverse relationship to lung volume, sRaw provides a relatively stable index with which to distinguish effects of disease from those of growth and development. sRaw is significantly increased in asthmatic patients, in those with wheezing disorders, and cystic fibrosis. It has also been shown to be a useful outcome measure for bronchodilator responsiveness studies.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>kPas</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.656" spread="1.929"/>
                    <measurement group_id="O2" value="1.668" spread="1.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.137" spread="1.087"/>
                    <measurement group_id="O2" value="1.223" spread="1.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.519" spread="0.878"/>
                    <measurement group_id="O2" value="-0.445" spread="1.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.686</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.074</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.386</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhalation Profile</title>
        <description>The patients' inhalation profile was assessed using a respiration belt. The inhalation profile through device was to be recorded at the moment of study drug administration. Respiratory belts are useful in measuring changes in thoracic or abdominal circumference during respiration. These measurements can indicate inhalation, expiration and breathing strength and can be used to derive breathing rate and characterize breathing patterns</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Inhalation Profile</title>
          <description>The patients' inhalation profile was assessed using a respiration belt. The inhalation profile through device was to be recorded at the moment of study drug administration. Respiratory belts are useful in measuring changes in thoracic or abdominal circumference during respiration. These measurements can indicate inhalation, expiration and breathing strength and can be used to derive breathing rate and characterize breathing patterns</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.565" spread="0.829"/>
                    <measurement group_id="O2" value="2.366" spread="1.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6MWT</title>
        <description>6MWT = 6 Minutes Walk Test (in meters). The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. The longer the walk in that timespan, the better the outcome.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>6MWT</title>
          <description>6MWT = 6 Minutes Walk Test (in meters). The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. The longer the walk in that timespan, the better the outcome.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="577.789" spread="69.222"/>
                    <measurement group_id="O2" value="583.789" spread="71.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.789" spread="72.250"/>
                    <measurement group_id="O2" value="598.158" spread="81.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" spread="12.428"/>
                    <measurement group_id="O2" value="14.368" spread="47.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.312</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10.368</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.659</ci_lower_limit>
            <ci_upper_limit>6.922</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg CR10 Scale (Pre-6MWT)</title>
        <description>Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case before the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, &quot;0 or nothing at all,&quot; means no breathlessness at all.&#xD;
The bottom of the scale, &quot;10 or maximal,&quot; means the most severe breathlessness that patients have ever experienced or could imagine experiencing.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Borg CR10 Scale (Pre-6MWT)</title>
          <description>Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case before the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, &quot;0 or nothing at all,&quot; means no breathlessness at all.&#xD;
The bottom of the scale, &quot;10 or maximal,&quot; means the most severe breathlessness that patients have ever experienced or could imagine experiencing.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.805" spread="1.160"/>
                    <measurement group_id="O2" value="0.670" spread="0.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.935" spread="1.241"/>
                    <measurement group_id="O2" value="0.820" spread="0.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from predose to postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.130" spread="0.734"/>
                    <measurement group_id="O2" value="0.150" spread="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.920</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.020</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.361</ci_lower_limit>
            <ci_upper_limit>0.321</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg CR10 Scale (Post-6MWT)</title>
        <description>Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case after the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, &quot;0 or nothing at all,&quot; means no breathlessness at all.&#xD;
The bottom of the scale, &quot;10 or maximal,&quot; means the most severe breathlessness that patients have ever experienced or could imagine experiencing.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>Borg CR10 Scale (Post-6MWT)</title>
          <description>Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case after the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, &quot;0 or nothing at all,&quot; means no breathlessness at all.&#xD;
The bottom of the scale, &quot;10 or maximal,&quot; means the most severe breathlessness that patients have ever experienced or could imagine experiencing.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.945" spread="2.029"/>
                    <measurement group_id="O2" value="1.580" spread="1.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.820" spread="1.753"/>
                    <measurement group_id="O2" value="1.375" spread="1.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.125" spread="1.188"/>
                    <measurement group_id="O2" value="-0.205" spread="0.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.818</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.080</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.513</ci_lower_limit>
            <ci_upper_limit>0.673</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS (Pre-6MWT)</title>
        <description>VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (In this case before the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from &quot;not breathless at all&quot;/no shortness of breath&quot; at the bottom or at the far left of the line, to &quot;shortness of breath as bad as can be&quot; on the top or on the right of the line, depending on the patient's opinion.&#xD;
measure of the difference in dyspnoea before and after treatment</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>VAS (Pre-6MWT)</title>
          <description>VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (In this case before the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from &quot;not breathless at all&quot;/no shortness of breath&quot; at the bottom or at the far left of the line, to &quot;shortness of breath as bad as can be&quot; on the top or on the right of the line, depending on the patient's opinion.&#xD;
measure of the difference in dyspnoea before and after treatment</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.550" spread="29.416"/>
                    <measurement group_id="O2" value="8.150" spread="25.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.034</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11.400</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.789</ci_lower_limit>
            <ci_upper_limit>20.011</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS (Post-6MWT)</title>
        <description>VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (in this case after the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from &quot;not breathless at all&quot;/no shortness of breath&quot; at the bottom or at the far left of the line, to &quot;shortness of breath as bad as can be&quot; on the top or on the right of the line, depending on the patient's opinion.</description>
        <time_frame>Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.</time_frame>
        <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Z7200</title>
            <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbohaler</title>
            <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
          </group>
        </group_list>
        <measure>
          <title>VAS (Post-6MWT)</title>
          <description>VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (in this case after the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from &quot;not breathless at all&quot;/no shortness of breath&quot; at the bottom or at the far left of the line, to &quot;shortness of breath as bad as can be&quot; on the top or on the right of the line, depending on the patient's opinion.</description>
          <population>Per-protocol (PP) population: all randomized patients who had correct study drug administration, without any major protocol deviations that could possibly have influenced the assessment of the product effect.</population>
          <units>percentage of value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.450" spread="23.962"/>
                    <measurement group_id="O2" value="15.850" spread="28.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The difference between the predose and postdose values of test product and the reference product was compared after applying Benjamini-Hochberg correction (BH) to control the false discovery rate and after Holm-Bonferroni correction (Holm) to control the family-wise error rate.</non_inferiority_desc>
            <p_value>0.427</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.600</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.323</ci_lower_limit>
            <ci_upper_limit>17.523</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Visit 2 (Time frame between day 7 and day 31) up to Follow-Up period (at maximum until day 83)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Z7200</title>
          <description>Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose - consisting of two inhalations - dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.&#xD;
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.</description>
        </group>
        <group group_id="E2">
          <title>Symbicort Turbohaler</title>
          <description>Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose -- consisting of two inhalations for a total dose budesonide/formoterol is 320 mcg/9 mcg - contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Meddra 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.0">Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations and Caveats not specified</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Luca Raiteri, MD</name_or_title>
      <organization>Zambon S.p.A.</organization>
      <phone>+39 02 6652461</phone>
      <email>luca.raiteri@zambongroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02227394
org study id: Z7200K02
secondary id: 2014-002151-26
nct id: NCT02227394
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated device: No
Primary objective:

      The primary objective of this study is to evaluate the effect of the products under
      investigation on functional respiratory imaging parameters and evaluate the particle
      deposition with Computational fluid dynamics (CFD).

      Secondary Objectives:

      The secondary objectives of this study were to assess the effect of test product and
      reference product on:

        -  lung function (spirometry and body plethysmography),

        -  exercise capacity (6-Minute Walking Test [6MWT] or equivalent method to measure exercise
           tolerance),

        -  dyspnea (Borg Category [C] Ratio [R] 10 [Borg CR10] scale and Visual Analogue Scale
           [VAS] dyspnea).

      Furthermore, the safety of the test product and reference product was evaluated through
      monitoring of AEs throughout the study.
This study is conducted as a randomized, double blind, double dummy two-period crossover
      study in stable asthma patients treated in accordance with the Global Initiative for Asthma
      (GINA) guidelines.

      On the first dosing day (Period 1, Visit 2), asthma stability was assessed based on review of
      pharmacologic treatment monitoring and FEV1 change from the previous visit. Patients were
      then randomized and allocated to one of two treatment sequences (i.e. test/reference or
      reference/test). Randomization codes were assigned strictly sequentially as patients became
      eligible for randomization. Patients received a single dose consisting of two inhalations of
      either the test product or the reference product, according to the assigned treatment
      sequence, in the presence of the Investigator or authorized site personnel. In addition,
      patients received two inhalations with matching placebo to the alternate treatment as a dummy
      inhaler to achieve double-blinding. All patients followed the same sequence of device
      inhalation, i.e. Symbicort or placebo Turbohaler first and Z7200 or placebo RS-01 inhaler
      second.

      On the second dosing day (Period 2, Visit 3), patients underwent the same asthma stability
      check and procedures as in Visit 2. Patients received a single dose consisting of two
      inhalations of the other treatment (reference in case test product was administered at Visit
      2 and vice versa) plus two inhalations with matching placebo to the alternate treatment.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Total Airway Volume (iVaw)
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: The Total Airway Volume is the amount of air that can be inhaled or exhaled during one respiratory cycle. This depicts the functions of the respiratory centers, respiratory muscles and the mechanics of the lung and chest wall. The higher the volume, the better the outcome.
measure: Total Airway Resistance (iRaw)
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: The Total Airway Resistance refers to degree of resistance to the flow of air through the respiratory tract during inspiration and expiration. The degree of resistance depends on many things, particularly the diameter of the airway and whether flow is laminar or turbulent. The higher the resistance, the worse the outcome.
In healthy men and women values range between 0.22 to 0.25 kPa/l.
measure: Number of Deposited Particles Per Pre-defined Airway Section
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: To evaluate the particle deposition in the lungs, the Computational Fluid Dynamic (CFD) was used. With CFD, based on the computed tomography (CT) derived geometries of the airways, it is possible to measure the resistance of all airways or subdivisions such as the smaller airways starting from the 3rd bifurcation onwards. The three-dimensional (3D) reconstruction in this CT-based imaging technique allows for an accurate measurement of local volume changes in the central and peripheral airways after the administration of the product. The increased sensitivity of this technique makes it possible to detect changes in airway caliber in early stages of asthma.
measure: Spirometry - FEV1
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: FEV1 = Forced Expiratory Volume in one second. Forced expiratory volume is the most important measurement of lung function. It measures how much air a person can exhale during a forced breath. The amount of air exhaled may be measured during the first (FEV1), second (FEV2), and/or third seconds (FEV3) of the forced breath.
Values of between 80% and 120% of the average value are considered normal.
measure: Spirometry - FVC
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: FVC = Forced Vital Capacity: is the total amount of air exhaled during the FEV test.
Values of between 80% and 120% of the average value are considered normal.
measure: Spirometry - PEF
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: PEF = Peak Expiratory Flow: is the maximum flow rate generated during a forceful exhalation, starting from full lung inflation.
PEF rate primarily reflects large airway flow and depends on the voluntary effort and muscular strength of the patient.
Normal adult peak expiratory flow ranges between around 400 and 700 liters per minute, although in older it can be lower.
measure: Spirometry - MEF25
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: MEF25 = Maximal Expiratory Flow at 25% of Forced Vital Capacity (FVC). This parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF25.
measure: Spirometry - MEF50
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: MEF50 = Maximal Expiratory Flow at 50% of Forced Vital Capacity (FVC). MEF50 is the flow where half of forced vital capacity (FVC) remains to be exhaled. Also this parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF50.
measure: Spirometry - FEV1/FVC Ratio
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: FEV1/FVC ratio = Tiffeneau Index. It is a calculated ratio use to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity. The result of this ratio is expressed as FEV1%.
Normal values are approximately 75%.
measure: Body Plethysmography - FRC
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: FRC = Functional Residual Capacity. It is the volume in the lungs at the end of passive expiration. It is determined by opposing forces of the expanding chest wall and the elastic recoil of the lung. A normal FRC = 1.7 to 3.5 L.
measure: Body Plethysmography - TLC
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: TLC = Total Lung Capacity. It is the volume of air in the lungs upon the maximum effort of inspiration. Among healthy adults, the average lung capacity is about 6 liters. Age, gender, body composition, and ethnicity are factors affecting the different ranges of lung capacity among individuals.
measure: Body Plethysmography - Raw
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: Raw = Airway resistance. It is defined as the change in transpulmonary pressure (proximal airway pressure minus the alveolar pressure) required to produce a unit flow of gas through the airways of the lung.
Are considered as normal all values up to 2.8 kPas/L
measure: Body Plethysmography - SRaw
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: SRaw = Specific airway resistance: also called volumic airway resistance. sRaw is a corrected index (Raw multiplied by thoracic gas volume) that describes airway behaviour regardless of lung volume. Normal values of sRaw in adult subjects have never been formally defined.
sRaw is the product of Functional Residual Capacity (FRC) and Airways Resistance (Raw) and can be calculated from the relationship of plethysmographic box pressure (Pbox) to flow during spontaneous breathing.
sRaw can be derived from the tangent of the slope of box Pressure/Flow. Since Raw has a strong inverse relationship to lung volume, sRaw provides a relatively stable index with which to distinguish effects of disease from those of growth and development. sRaw is significantly increased in asthmatic patients, in those with wheezing disorders, and cystic fibrosis. It has also been shown to be a useful outcome measure for bronchodilator responsiveness studies.
measure: Inhalation Profile
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: The patients' inhalation profile was assessed using a respiration belt. The inhalation profile through device was to be recorded at the moment of study drug administration. Respiratory belts are useful in measuring changes in thoracic or abdominal circumference during respiration. These measurements can indicate inhalation, expiration and breathing strength and can be used to derive breathing rate and characterize breathing patterns
measure: 6MWT
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: 6MWT = 6 Minutes Walk Test (in meters). The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. The longer the walk in that timespan, the better the outcome.
measure: Borg CR10 Scale (Pre-6MWT)
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case before the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, "0 or nothing at all," means no breathlessness at all.
The bottom of the scale, "10 or maximal," means the most severe breathlessness that patients have ever experienced or could imagine experiencing.
measure: Borg CR10 Scale (Post-6MWT)
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case after the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, "0 or nothing at all," means no breathlessness at all.
The bottom of the scale, "10 or maximal," means the most severe breathlessness that patients have ever experienced or could imagine experiencing.
measure: VAS (Pre-6MWT)
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (In this case before the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from "not breathless at all"/no shortness of breath" at the bottom or at the far left of the line, to "shortness of breath as bad as can be" on the top or on the right of the line, depending on the patient's opinion.
measure of the difference in dyspnoea before and after treatment
measure: VAS (Post-6MWT)
time frame: Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.
description: VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (in this case after the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from "not breathless at all"/no shortness of breath" at the bottom or at the far left of the line, to "shortness of breath as bad as can be" on the top or on the right of the line, depending on the patient's opinion.
arm group label: Z7200 - Symbicort® Turbohaler
arm group type: Experimental
description: The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the test product (Z7200) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the second dosing day (Period 2, Visit 3).
Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.
Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.
Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided.
arm group label: Symbicort® Turbohaler - Z7200
arm group type: Experimental
description: The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the test product (Z7200) on the second dosing day (Period 2, Visit 3).
Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.
Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg).
intervention type: Drug
intervention name: Z7200
description: Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).
At visit 2 or 3 (cross-over design)
arm group label: Symbicort® Turbohaler - Z7200
arm group label: Z7200 - Symbicort® Turbohaler
other name: Test product
intervention type: Drug
intervention name: Symbicort® Turbohaler®
description: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
arm group label: Symbicort® Turbohaler - Z7200
arm group label: Z7200 - Symbicort® Turbohaler
other name: Reference product
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Wilfried De Backer, MD, PhD
role: Principal Investigator
affiliation: University Hospital, Antwerp
facility: 
country: Belgium
responsible party type: Sponsor
mesh term: Asthma
mesh term: Budesonide, Formoterol Fumarate Drug Combination
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
limitations and caveats: Limitations and Caveats not specified
point of contact: 